Serum IL-18 is increased at early postburn period in moderately burned patients

Mediators of Inflammation

Volumn 2006, Issue , 2006, Pages

  Coban, Y Kenan ^a   Aral, Murat ^a  

^a KAHRAMANMARAS SUTCU IMAM UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 18; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ADOLESCENT; ADULT; ARTICLE; BLOOD ANALYSIS; BODY MASS; BODY SURFACE; BURN; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HOSPITAL ADMISSION; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SURVIVAL RATE; BLOOD; IMMUNE SYSTEM; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY; TIME;

BACTERIA (MICROORGANISMS);

ADOLESCENT; ADULT; BODY MASS INDEX; BURNS; CYTOKINES; FEMALE; HUMANS; IMMUNE SYSTEM; INFLAMMATION; INTERLEUKIN-18; INTERLEUKIN-6; MALE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33645554035     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/MI/2006/16492     Document Type: Article

References (25)

1. Ueyama M, Maruyama I, Osame M, Sawada Y. Marked increase in plasma interleukin-6 in burn patients. The Journal of Laboratory and Clinical Medicine. 1992;120(5):693-698.
2. Endo S, Inada K, Yamada Y, et al. Plasma tumour necrosis factor-α (TNF-α) levels in patients with burns. Burns. 1993;19(2):124-127.
3. Dugan AL, Malarkey WB, Schwemberger S, Jauch EC, Ogle CK, Horseman ND. Serum levels of prolactin, growth hormone, and cortisol in burn patients: correlations with severity of burn, serum cytokine levels, and fatality. Journal of Burn Care & Rehabilitation. 2004;25(3):306-313.
4. de Bandt JP, Chollet-Martin S, Hernvann A, et al. Cytokine response to burn injury: relationship with protein metabolism. The Journal of Trauma. 1994;36(5):624-628.
5. Yeh FL, Lin WL, Shen HD. Changes in circulating levels of an anti-inflammatory cytokine interleukin 10 in burned patients. Burns. 2000;26(5):454-459.
6. Yeh FL, Lin WL, Shen HD, Fang RH. Changes in circulating levels of interleukin 6 in burned patients. Burns. 1999;25(2):131-136.
7. Yeh FL, Lin WL, Shen HD, Fang RH. Changes in serum tumour necrosis factor-α in burned patients. Burns. 1997;23(1):6-10.
8. Takeuchi D, Yoshidome H, Kato A, et al. Interleukin 18 causes hepatic ischemia/reperfusion injury by suppressing anti-inflammatory cytokine expression in mice. Hepatology. 2004;39(3):699-710.
9. Lauw FN, Branger J, Florquin S, et al. IL-18 improves the early antimicrobial host response to pneumococcal pneumonia. The Journal of Immunology. 2002;168(1):372-378.
10. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Critical Care Medicine. 1992;20(6):864-874.
11. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annual Review of Immunology. 2001;19:423-474.
12. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 is a unique cytokine that stimulates both Th1 and Th2 responses depending on its cytokine milieu. Cytokine & Growth Factor Reviews. 2001;12(1):53-72.
13. Okamura H, Tsutsi H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature. 1995;378(6552):88-91.
14. Ushio S, Namba M, Okura T, et al. Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein. The Journal of Immunology. 1996;156(11):4274-4279.
15. Billiau A. Interteron-gamma: biology and role in pathogenesis. Advances in Immunology. 1996;62:61-130.
16. Döcke W-D, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nature Medicine. 1997;3(6):678-681.
17. Conti B, Jahng JW, Tinti C, Son JH, Joh TH. Induction of interferon-γ inducing factor in the adrenal cortex. The Journal of Biological Chemistry. 1997;272(4):2035-2037.
18. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993;75(6):1169-1178.
19. McKay A, Komai-Koma M, MacLeod KJ, et al. Interleukin-18 levels in induced sputum are reduced in asthmatic and normal smokers. Clinical & Experimental Allergy. 2004;34(6):904-910.
20. Giugliano F, Esposito K, Di Palo C, et al. Erectile dysfunction associates with endothelial dysfunction and raised proinflammatory cytokine levels in obese men. Journal of Endocrinological Investigation. 2004;27(7):665-669.
21. Wang HM, Cao WF, Peng YZ, Xiao GX, Yang XY. Changes in plasma levels of LPS, TNF-α and IL-6 in burn patients with severe infection treated with Imipenem or Cefoperazone [in Chinese]. Zhonghua Shao Shang Za Zhi. 2004;20(2):95-97.
22. Kinoshita M, Seki S, Ono S, Shinomiya N, Hiraide H. Paradoxical effect of IL-18 therapy on the severe and mild Escherichia coli infections in burn-injured mice. Annals of Surgery. 2004;240(2):313-320.
23. Netea MG, Fantuzzi G, Kullberg BJ, et al. Neutralization of IL-18 reduces neutrophil tissue accumulation and protects mice against lethal Escherichia coli and Salmonella typhimurium endotoxemia. The Journal of Immunology. 2000;164(5):2644-2649.
24. Liu B, Mori I, Hossain MJ, Dong L, Takeda K, Kimura Y. Interleukin-18 improves the early defence system against influenza virus infection by augmenting natural killer cell-mediated cytotoxicity. Journal of General Virology. 2004;85(pt 2):423-428.
25. Kohno K, Kataoka J, Ohtsuki T, et al. IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. The Journal of Immunology. 1997;158(4):1541-1550.